Sugi Predict

Sugi Predict / Compounds / L-Nil

L-Nil

L-Nil

SCHEMBL934874

CC(=N)NCCCCC(N)C(=O)O

nearest known ligand 0.50

Full drug profile on Sugi Atlas →

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
▸ ARG2 P78540 4/20 0.50
▸ ARG1 P05089 3/20 0.50
▸ GSR P00390 1/20 0.50
▸ OTC P00480 1/20 0.49
▸ NOS2 P35228 6/20 0.49
▸ NOS1 P29475 5/20 0.49
▸ NOS3 P29474 4/20 0.49
▸ CYP1A2 P05177 1/20 0.49
▸ CYP3A4 P08684 1/20 0.49
▸ TSHR P16473 1/20 0.49
▸ BLM P54132 1/20 0.47
▸ DPP7 Q9UHL4 1/20 0.46
▸ MEN1 O00255 1/20 0.46
▸ CYP2C19 P33261 1/20 0.46
▸ KMT2A Q03164 1/20 0.46
▸ GNAI3 P08754 1/20 0.44
▸ GNAO1 P09471 1/20 0.44
▸ GNAI1 P63096 1/20 0.44
▸ NOD1 Q9Y239 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
L-Nil SCHEMBL31540966 1.00 ARG2 (0.50) ARG2ARG1GSROTCNOS2
L-Nil SCHEMBL322091 1.00 ARG2 (0.50) ARG2ARG1GSROTCNOS2
L-Nil SCHEMBL677147 0.98 ARG2 (0.51) ARG2ARG1GSROTCNOS2
L-Nil SCHEMBL1321685 0.98 ARG2 (0.51) ARG2ARG1GSROTCNOS2
SCHEMBL8065968 0.98 NOS2 (0.50) ARG2ARG1GSROTCNOS2
L-Nil SCHEMBL7977021 0.98 ARG2 (0.51) ARG2ARG1GSROTCNOS2
L-Nil SCHEMBL7974005 0.98 ARG2 (0.51) ARG2ARG1GSROTCNOS2
Hydrochloric Acid SCHEMBL8470176 0.97 ARG2 (0.50) ARG2ARG1GSROTCNOS2
L-Nio SCHEMBL4424485 0.95 OTC (0.54) ARG2ARG1GSROTCNOS2
L-Nio SCHEMBL1569333 0.95 OTC (0.54) ARG2ARG1GSROTCNOS2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 39 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250276085-A1 SYNTHETIC MULTIDOMAIN PEPTIDE BIOMATERIALS THAT INHIBIT INDUCIBLE NITRIC OXIDE SYNTHASE WILLIAM MARSH RICE UNIVERSITY (US) 2025-09-04 — — US claimed
US-12251449-B2 Synthetic multidomain peptide biomaterials that inhibit inducible nitric oxide synthase WILLIAM MARSH RICE UNIVERSITY (US) 2025-03-18 — — US claimed
US-20210205468-A1 SYNTHETIC MULTIDOMAIN PEPTIDE BIOMATERIALS THAT INHIBIT INDUCIBLE NITRIC OXIDE SYNTHASE WILLIAM MARSH RICE UNIVERSITY (US) 2021-07-08 — — US claimed
WO-2010037095-A2 AGENTS AND METHODS FOR THE TREATMENT OF CANCER NOMETICS (CA) 2010-04-01 — — WO claimed
US-7087627-B1 Combinations for the treatment of diseases involving angiogenesis ANGIOGENE PHARMACEUTICALS LTD. (GB) 2006-08-08 — — US claimed
EP-0749418-B1 L-N6 -(1-IMINOETHYL)LYSINE DERIVATIVES USEFUL AS NITRIC OXIDE SYNTHASE INHIBITORS SEARLE & CO (US) 2000-08-30 — — EP claimed
EP-0749418-A1 L-N6 -(1-IMINOETHYL)LYSINE DERIVATIVES USEFUL AS NITRIC OXIDE SYNTHASE INHIBITORS G.D. SEARLE & CO. (US) 1996-12-27 — — EP claimed
WO-1995024382-A1 L-N6-(1-IMINOETHYL)LYSINE DERIVATIVES USEFUL AS NITRIC OXIDE SYNTHASE INHIBITORS G.D. SEARLE & CO. (US) 1995-09-14 — — WO claimed
US-20250276085-A1 SYNTHETIC MULTIDOMAIN PEPTIDE BIOMATERIALS THAT INHIBIT INDUCIBLE NITRIC OXIDE SYNTHASE WILLIAM MARSH RICE UNIVERSITY (US) 2025-09-04 — — US disclosed
US-20250276085-A1 SYNTHETIC MULTIDOMAIN PEPTIDE BIOMATERIALS THAT INHIBIT INDUCIBLE NITRIC OXIDE SYNTHASE WILLIAM MARSH RICE UNIVERSITY (US) 2025-09-04 — — US disclosed
US-12251449-B2 Synthetic multidomain peptide biomaterials that inhibit inducible nitric oxide synthase WILLIAM MARSH RICE UNIVERSITY (US) 2025-03-18 — — US disclosed
US-12251449-B2 Synthetic multidomain peptide biomaterials that inhibit inducible nitric oxide synthase WILLIAM MARSH RICE UNIVERSITY (US) 2025-03-18 — — US disclosed
CN-118561798-A Flavonoid compound and preparation method and application thereof 江西省人民医院 2024-08-30 — — CN disclosed
US-11911349-B2 Rapidly improving vascular conditions by administering vitamin K NATTOPHARMA AS (NO) 2024-02-27 — — US disclosed
EP-1492567-A1 FORMULATIONS AND METHODS OF USING NITRIC OXIDE MIMETICS IN CANCER TREATMENT Cellegy Pharmaceuticals, Inc (US) 2005-01-05 — — EP disclosed
WO-2003074082-A1 FORMULATIONS AND METHODS OF USING NITRIC OXIDE MIMETICS IN CANCER TREATMENT CELLEGY PHARMACEUTICALS, INC. (CA) 2003-09-12 — — WO disclosed
WO-2001005748-A1 OLIGOMERIC AMINO ACID DERIVATIVES USEFUL AS NITRIC OXIDE SYNTHASE INHIBITORS MONSANTO COMPANY (US) 2001-01-25 — — WO disclosed
US-6143790-A ENZYME INHIBITORS G.D. SEARLE & CO. (US) 2000-11-07 — — US disclosed
EP-0749418-B1 L-N6 -(1-IMINOETHYL)LYSINE DERIVATIVES USEFUL AS NITRIC OXIDE SYNTHASE INHIBITORS SEARLE & CO (US) 2000-08-30 — — EP disclosed
WO-1995024382-A1 L-N6-(1-IMINOETHYL)LYSINE DERIVATIVES USEFUL AS NITRIC OXIDE SYNTHASE INHIBITORS G.D. SEARLE & CO. (US) 1995-09-14 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20210205468-A1 SYNTHETIC MULTIDOMAIN PEPTIDE BIOMATERIALS THAT INHIBIT INDUCIBLE NITRIC OXIDE SYNTHASE STING1, CGAS, GMPS ARG2 53/4885ARG1 5/4885GSR 1070/4885
US-12251449-B2 Synthetic multidomain peptide biomaterials that inhibit inducible nitric oxide synthase STING1, CGAS, GMPS ARG2 53/4885ARG1 5/4885GSR 1070/4885
US-20250276085-A1 SYNTHETIC MULTIDOMAIN PEPTIDE BIOMATERIALS THAT INHIBIT INDUCIBLE NITRIC OXIDE SYNTHASE STING1, CGAS, GMPS ARG2 53/4885ARG1 5/4885GSR 1070/4885
US-11911349-B2 Rapidly improving vascular conditions by administering vitamin K PROC, VDR, VEGFA ARG2 444/4885ARG1 277/4885GSR 898/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.